CN110141661A - Botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model - Google Patents

Botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model Download PDF

Info

Publication number
CN110141661A
CN110141661A CN201910384771.8A CN201910384771A CN110141661A CN 110141661 A CN110141661 A CN 110141661A CN 201910384771 A CN201910384771 A CN 201910384771A CN 110141661 A CN110141661 A CN 110141661A
Authority
CN
China
Prior art keywords
protein
ahc
albumen
sequence
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910384771.8A
Other languages
Chinese (zh)
Inventor
杨慧盈
干长姣
周冬生
孙岩松
法云智
高波
邱业峰
焦周光
郝淮杰
杨文慧
胡凌飞
赵月娥
于学东
熊小路
焦俊
殷喆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Academy of Military Medical Sciences AMMS of PLA
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Priority to CN201910384771.8A priority Critical patent/CN110141661A/en
Publication of CN110141661A publication Critical patent/CN110141661A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways

Abstract

The invention discloses a kind of botulinal toxin A Hc vaccine liquid aersol lungs to deliver immune mouse model.The present invention provides a kind of BoNT A vaccine, effective component is the aerosol of particular solution；Contain specific protein and Mucosal Adjuvants in the particular solution；The specific protein is AHc albumen or the fusion protein with AHc albumen；The quality proportioning of specific protein and Mucosal Adjuvants is 1:0.5-1.5.AHc albumen is protein shown in the sequence 1 of sequence table.The present invention has selected a kind of recombinant protein A Hc subunit vaccine, and has studied internal and external effect of AHc subunit vaccine using lung delivering immunization ways for the first time.Vaccine can protect mouse and attack from fatal botulinum toxin type A, and transtracheal, which carries out lung delivering, can directly reach sample lung's target organ, and directly, medicament-saving provides a kind of new technological means for sucking infection and treatment for effect.

Description

Botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model
Technical field
The present invention relates to a kind of botulinal toxin A Hc vaccine liquid aersol lungs to deliver immune mouse model.
Background technique
Botulinum toxin (Botulinum neurotoxin, BoNT) is the mind generated in the environment of anaerobism by clostridium botulinum It is a kind of extremely strong protein toxin of toxicity through exotoxin.Botulinum toxin is typical A-B type nerve exotoxin, by inhibiting mind Release through ACh vesicle at neuromuscular junction, the impulse conduction at block nerves neuromuscular junction, eventually results in skeletal muscle Paralysis, respiratory failure and it is dead, be the strongest albumen of known toxicity.
The duplex structure that botulinum toxin is made of light chain (50kDa) and heavy chain (100kDa), is connected by disulfide bond.Light chain It is toxic component.Heavy chain is the toxin receptor of nerve cell, itself does not have activity, is transmembrane transport and the entrance for mediating toxin Necessary to cell.There are two cross-films for botulinum toxin, and there are two disulfide bond, a disulfide bond is located at intramolecular, two sulphur Key mapping is in intermolecular.Native botulinum toxin and hemagglutinin, non toxin non hemaglutinin albumen constitute precursor toxin together, and (toxin is compound Object), molecular weight about 300kDa~900kDa, precursor toxin is with good stability, can long-term preservation without losing activity.
Difference of the botulinum toxin according to Venom antigens, is divided into 7 kinds of serotypes (A type, Type B, c-type, D type, E type, F type and G Type), wherein A, B, E and F type can cause the mankind to be poisoned, wherein it is most strong with the toxicity of A type, it is in biotoxin and chemical toxicant The strongest substance of toxicity, caused clinical symptoms also much overweight Type B and E type.BoNTs toxicity is big, and property is stablized, and is easy to quilt It is prepared into biological warfare agent application, seriously endangers public health and safety.It studies the pathogenic mechanism of botulinum toxin aerosol and is immunized Protection, attacking anti-biological weapons war and anti-terrorism has important military significance.
Vaccine inoculation is the most effective Medical Countermeasure for preventing botulism.Current commercial vaccine is toxoid (holotoxin inactivated).Toxoid vaccine has side effect, such as locally and systemically reacts, and is receiving second of injection Increase in individual.The researchs such as the evaluation of toxicological effect, vaccine protecting effect of BoNTs all be unable to do without the foundation of animal model.Mesh Before, the research for liquid aersol or dry powder aerosol etc. mostly uses mouse mouth and nose exposed and systemic exposure model, both Although method to experimental animal hurtless measure, can not accurate quantification dosage, sample is lost larger and held in exposure tower Easily settle.And relevant instrument and equipment volume is big, expensive.
Summary of the invention
The object of the present invention is to provide a kind of botulinal toxin A Hc vaccine liquid aersol lungs to deliver immune mouse model.
The present invention provides a kind of BoNT A vaccine, effective component is the aerosol of particular solution；It is described Contain specific protein and Mucosal Adjuvants in particular solution；The specific protein is AHc albumen or the fusion with AHc albumen Albumen；The quality proportioning of specific protein and Mucosal Adjuvants is 1:0.5-1.5.
The quality proportioning of specific protein and Mucosal Adjuvants concretely 1:1.
Fusion protein with AHc albumen obtains for the N-terminal and/or C-terminal fusion tag albumen in AHc albumen. Label protein and AHc albumen can direct fusion connection, the link peptide fusion connection of 1-10 amino acid residue can also be passed through. Fusion protein with AHc albumen concretely AHc-His6Albumen.AHc-His63 institute of sequence of albumen concretely sequence table The protein shown.
In the particular solution, also contain buffer.The buffer can be PBS buffer solution.The buffer is more specific It can be the PBS buffer solution of pH7.2,0.01M.
The particular solution can be specifically made of specific protein (specific protein solution), Mucosal Adjuvants and buffer.
In every 50 microlitres of particular solutions, it can specifically contain 20 μ g specific proteins and 20 μ g Mucosal Adjuvants.
The Mucosal Adjuvants concretely CpG.
The present invention also protects a kind of for preventing and/or treating the external member of BoNT A poisoning, including specific egg White, Mucosal Adjuvants and liquid aersol lung delivery apparatus；The specific protein is AHc albumen or melting with AHc albumen Hop protein；The quality proportioning of specific protein and Mucosal Adjuvants is 1:0.5-1.5.
The quality proportioning of specific protein and Mucosal Adjuvants concretely 1:1.
Fusion protein with AHc albumen obtains for the N-terminal and/or C-terminal fusion tag albumen in AHc albumen. Label protein and AHc albumen can direct fusion connection, the link peptide fusion connection of 1-10 amino acid residue can also be passed through. Fusion protein with AHc albumen concretely AHc-His6Albumen.AHc-His63 institute of sequence of albumen concretely sequence table The protein shown.
The Mucosal Adjuvants concretely CpG.
The present invention also protects a kind of BoNT A vaccine, and effective component is the aerosol of specific protein solution； The specific protein is AHc albumen or the fusion protein with AHc albumen.
Fusion protein with AHc albumen obtains for the N-terminal and/or C-terminal fusion tag albumen in AHc albumen. Label protein and AHc albumen can direct fusion connection, the link peptide fusion connection of 1-10 amino acid residue can also be passed through. Fusion protein with AHc albumen concretely AHc-His6Albumen.AHc-His63 institute of sequence of albumen concretely sequence table The protein shown.
In the particular solution, also contain buffer.The buffer can be PBS buffer solution.The buffer is more specific It can be the PBS buffer solution of pH7.2,0.01M.
The particular solution can be specifically made of specific protein (specific protein solution) and buffer.
In every 50 microlitres of particular solutions, it can specifically contain 20 μ g specific proteins.
The present invention also protects a kind of for preventing and/or treating the external member of BoNT A poisoning, including specific egg White and liquid aersol lung delivery apparatus；The specific protein is AHc albumen or the fusion protein with AHc albumen.
Fusion protein with AHc albumen obtains for the N-terminal and/or C-terminal fusion tag albumen in AHc albumen. Label protein and AHc albumen can direct fusion connection, the link peptide fusion connection of 1-10 amino acid residue can also be passed through. Fusion protein with AHc albumen concretely AHc-His6Albumen.AHc-His63 institute of sequence of albumen concretely sequence table The protein shown.
The present invention also protects a kind of for preventing and/or treating the vaccine of BoNT A poisoning, including specific egg White and Mucosal Adjuvants；The specific protein is AHc albumen or the fusion protein with AHc albumen；Specific protein and mucous membrane The quality proportioning of immunologic adjuvant is 1:0.5-1.5.
The quality proportioning of specific protein and Mucosal Adjuvants concretely 1:1.
Fusion protein with AHc albumen obtains for the N-terminal and/or C-terminal fusion tag albumen in AHc albumen. Label protein and AHc albumen can direct fusion connection, the link peptide fusion connection of 1-10 amino acid residue can also be passed through. Fusion protein with AHc albumen concretely AHc-His6Albumen.AHc-His63 institute of sequence of albumen concretely sequence table The protein shown.
The Mucosal Adjuvants concretely CpG.
The vaccine is lung delivery of vaccines.
The present invention also protects specific protein, Mucosal Adjuvants and lung delivery apparatus preparing the application in product；It is described The purposes of product is to prevent and/or treat BoNT A poisoning；The specific protein is AHc albumen or has AHc egg White fusion protein；The quality proportioning of specific protein and Mucosal Adjuvants is 1:0.5-1.5.
The quality proportioning of specific protein and Mucosal Adjuvants concretely 1:1.
Fusion protein with AHc albumen obtains for the N-terminal and/or C-terminal fusion tag albumen in AHc albumen. Label protein and AHc albumen can direct fusion connection, the link peptide fusion connection of 1-10 amino acid residue can also be passed through. Fusion protein with AHc albumen concretely AHc-His6Albumen.AHc-His63 institute of sequence of albumen concretely sequence table The protein shown.
The Mucosal Adjuvants concretely CpG.
Any description above AHc albumen is following (a1) or (a2):
(a1) protein shown in the sequence 1 of sequence table；
(a2) protein shown in sequence 1 in sequence table by the substitution of one or several amino acid residues and/or is lacked Mistake and/or addition and protein with the same function as derived from it.
The present invention also protects a kind of method for preparing botulinum toxin intoxicating animal model, includes the following steps: meat poisoning poison Plain solution is delivered to experimental animal by liquid aersol lung, obtains botulinum toxin intoxicating animal model.The model can directly by Tested material is delivered to mouse lung with aerosol form, with strong points, reproducible, and tested material can be studied with accurate quantitative analysis to small The protecting effect of mouse.
The botulinum toxin is BoNT A.
The experimental animal is mouse.The experimental animal is specially BALB/c mouse.
The toxic dose of attacking of botulinum toxin is 125ng/kg-375ng/kg weight.Botulinum toxin attacks toxic dose concretely 125ng/kg weight, 187.5ng/kg weight, 250ng/kg weight, 312.5ng/kg weight or 375ng/kg weight.
For the botulinum toxin solution single delivery to experimental animal, dosage delivered is every 50 μ L of experimental animal.
The present invention has selected a kind of recombinant protein A Hc subunit vaccine, and is had studied for the first time using lung delivering immunization ways Internal and external effect of AHc subunit vaccine.Prove that our candidate vaccine can protect mouse from fatal A type meat poisoning Toxin attacks, transtracheal, which carries out lung delivering, can directly reach sample lung's target organ, and effect is direct, medicament-saving, to inhale Enter infection and treatment provides a kind of new technological means.
Detailed description of the invention
Fig. 1 is the survival rate of low dosage subgroup.
Fig. 2 is the survival rate of middle dosage subgroup.
Fig. 3 is the survival rate of high dose subgroup.
Fig. 4 is the concentration of IgG antibody in serum.
Fig. 5 is the concentration of antibody in serum IgG 1.
Fig. 6 is the concentration of IgG2a antibody in serum.
Fig. 7 is the concentration of IgG2b antibody in serum.
Specific embodiment
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments Method is unless otherwise specified conventional method.Test material as used in the following examples is unless otherwise specified certainly What routine biochemistry reagent shop was commercially available.Quantitative test in following embodiment is respectively provided with three repeated experiments, as a result makes even Mean value.
BALB/c mouse (SPF grades of females, 6-7 weeks): Beijing Vital River Experimental Animals Technology Co., Ltd.；Experimental animal Credit number: SCXK (capital) 2016-0006).
Hand-held liquid aerosol lung delivery apparatus: intelligent flourish and Science and Technology Ltd. the pulmonary fluid in Beijing is quantitatively atomized Device.
Unless otherwise specified, PBS buffer solution used in embodiment is the PBS buffer solution of pH7.2,0.01M.
The preparation of embodiment 1, albumen
One, the preparation of BoNT A (BoNT/A)
Prepare BoNT A.According to document (" a kind of easy-to-use botulinum toxin type A activity test method Establish ", Liu Jing) in record method prepared.Using A type clostridium botulinum (Clostridium botulinum typeA) 62A is first carried out increasing bacterium and is produced poison culture, then precipitated and extracted, then carry out ammonium sulfate precipitation (60% saturation degree) With removal nucleic acid, gel filtration and ion-exchange chromatography are then carried out, BoNT A solution is obtained.Specific steps are shown in Document.
BoNT A solution is taken, BCA method measures protein concentration, protein concentration 0.15mg/mL.
Two, the preparation of AHc albumen
Nontoxic 50kD carboxyl-terminal fragment in AHc albumen, that is, BoNT A heavy chain.Such as sequence table of AHc albumen Sequence 1 shown in, AHc albumen shown in the sequence 1 of DNA molecular polynucleotide shown in the sequence 2 of sequence table.
1, the building of recombinant vector pTIG-Trx
Recombinant vector pTIG-Trx: the specific DNA fragment in carrier pET-22b (+) is substituted by 4 institute of sequence of sequence table The DNA molecular shown obtains recombinant vector pTIG-Trx.Specific DNA fragment refers in carrier pET-22b (+) from Nde I digestion Identification sequence starts to His6Terminator codon after label coding sequence terminates.
In DNA molecular shown in the sequence 4 of sequence table, 4-360 nucleotide are the encoder block of Trx gene, 360- 1676 nucleotide are AHc-His6The encoder block of albumen.
Trx gene encoding thioredoxin.Thioredoxin is the auxilin for participating in nascent protein peptide chain folding, when weight When histone co-expresses therewith, it can promote the destination protein that downstream is folding and obtains correctly folding by isomerization reaction, In addition, can also enhance the formation of the disulfide bond of intracellular protein, expression product is made to be not easy to form inclusion body.
AHc-His6Albumen is the C-terminal fusion His in AHc albumen6What label obtained (has 2 amino acid between them The interval of residue), as shown in the sequence 3 of sequence table.
2, recombinant vector pTIG-Trx is imported into e. coli bl21 (DE3), obtains recombinant bacterium.
3, the recombinant bacterium for obtaining step 2 is seeded to the LB liquid medium of the ampicillin containing 100mg/mL, 37 DEG C, 250rpm is cultivated to logarithmic growth phase (OD600nmAbout 0.4-0.6).
4, after completing step 3, being added in system IPTG and makes its concentration 0.2mmol/L in system, and then 30 DEG C, 250rpm Fiber differentiation 5 hours, then collect bacterial sediment.
5, the bacterial sediment for taking step 4 to obtain carries out ultrasonication, collects supernatant.
6, the supernatant for taking step 5 to obtain, using Ni-NTA affinity column (be purchased from Pharmacia Corp) and referring to saying Bright book carries out protein purification, and the solution of purified pool is transferred in bag filter, is dialysed in PBS buffer solution, is obtained AHc-His6Protein solution.
7, protein concentration detects
Take AHc-His6Protein solution, BCA method measure protein concentration, protein concentration 3.092mg/mL.
The half lethal dose research that embodiment 2, the delivering of BoNT A solution aerosol lung are infected
BoNT A is measured to the half lethal dose (LD of mouse using Kou Shifa (Karber) is improved50)。
5 dosage are arranged attacks malicious group, i.e., and the 1st group to the 5th group, every group of 5 BALB/c mouses (every mouse weight 15- 17g).Treatment process: be first injected intraperitoneally 1% yellow Jackets anaesthetized (anaesthetize before 3h fasting and prohibit drink, yellow Jackets Dosage is 60mg/kg weight, 1% yellow Jackets normal saline)；After holonarcosis, mouse is fixed on one With desktop on the operation plate of about 45° angle, the right hand is gently clamped mouse tongue with pincet and is lifted up, and left hand takes band light source Mouse laryngoscope make the exposure of its glottis, see after air pipe inlet and be inserted into the fog-spray nozzle of hand-held liquid aerosol lung delivery apparatus Tracheae quickly attacks malicious (the malicious volume of attacking of every mouse is 50 μ L)；It attacks poison and completes backed off after random fog-spray nozzle and laryngoscope, and after continuation of insurance The posture 10-20s that mouse head is in higher position is held, then mouse is put into cage, it is warming until small to mouse with infrared lamp Mouse is awake.Attack poison use embodiment 1 preparation BoNT A solution dilution (solvent is PBS buffer solution), the 1st The toxic dose of attacking of group to the 5th group is followed successively by 375ng/kg weight, 312.5ng/kg weight, 250ng/kg weight, 187.5ng/kg Weight, 125ng/kg weight.
Blank control group, 5 BALB/c mouses (every mouse weight 15-17g), with isometric PBS buffer solution generation are set For the dilution of BoNT A solution.
It is used as 1 day within every 24 hours, respectively at attacking malicious 0 moment, attacks poison after 1 day, attack poison after 2 days, attack poison after 3 days, attack poison 4 days Afterwards, attack poison 5 days after, attack poison 6 days after, attack poison 7 days after, record survival mice quantity, calculate the death rate, the results are shown in Table 1.Using changing Half lethal dose (LD is calculated into Kou Shifa formula50).Half lethal dose is 287.8ng/kg weight.
Table 1
It is used as 1 day within every 24 hours, respectively at attacking malicious 0 moment, attacks poison after 1 day, attack poison after 2 days, attack poison after 3 days, attack poison 4 days Afterwards, attack poison 5 days after, attack poison 6 days after, administration 7 days after, observe and record mouse illness (collapse, inactive, hair is upright, polyp Sample, refusal feed or drinking-water, and ptosis in some cases etc.).Mouse attack it is 6-12 hours malicious after collapse, no Activity, hair is upright, polypoid, refusal feed or drinking-water, to symptoms slow in reacting etc. after outside stimulus.Subsequent section mouse disease Shape gradually aggravates, and attacks in the higher group of toxic dose, has clinical symptoms mouse quantity more.
Embodiment 3, the research of AHc protein vaccine liquid aersol inhalational immunization
CpG, full name are Class B CpG oligonucleotide (B class CpG ODN), have immune activation function Can, it is the immunostimulant for people or mouse TLR 9, is a kind of typical Mucosal Adjuvants.CpG used in embodiment, The product for being tlrl-2006 for sigma Products catalog number (Cat.No.), the website links of the product are as follows: https: // www.invivogen.com/odn2006。
Aluminium adjuvanthttps://www.invivogen.com/alhydrogel。
One, the immune processing of grouping
BALB/c mouse (totally 80) is randomly divided into four groups, three test groups and a control group.
Test group 1 (15), also known as liquid aersol AHc group or lung delivery group: immune CpG and AHc-His6Albumen (by AHc-His prepared by embodiment 16Protein solution provides), single immunization dosage is " 20 μ of CpG g/, AHc-His6Protein 20 μ G/ is only ", single immunization volume is 50 microlitres/(supplying volume with PBS buffer solution).Test group 1 is molten using hand-held liquid gas Glue lung delivery apparatus is immunized.Immunologic process: first 1% yellow Jackets of intraperitoneal injection of anesthesia are anaesthetized, and (3h prohibits before anaesthetizing Food and taboo drink, the dosage of yellow Jackets are 60mg/kg weight, 1% yellow Jackets normal saline)；Completely After anesthesia, mouse is fixed on one and desktop on the operation plate of about 45° angle, and the right hand gently clamps mouse tongue simultaneously with pincet It is lifted up, left hand takes the mouse laryngoscope with light source to make the exposure of its glottis, sees hand-held liquid aerosol after air pipe inlet The fog-spray nozzle of lung delivery apparatus is inserted into tracheae tachysynthesis；It is immune to complete backed off after random fog-spray nozzle and laryngoscope, and continue to keep mouse Head is in the posture 10-20s of higher position, and then mouse is put into cage, warming until mouse is awake to mouse with infrared lamp.
Test group 2 (15), also known as liquid aersol CpG group or CpG group: immune CpG, single immunization dosage are " CpG 20 μ g/ are only ", single immunization volume is 50 microlitres/(supplying volume with PBS buffer solution).Test group 2 uses hand-held liquid gas Colloidal sol lung delivery apparatus is immunized, and method is the same as test group 1.
Test group 3 (15), also known as subcutaneous AHc group or subcutaneous group: immune aluminium adjuvant and AHc-His6Albumen is (by embodiment The AHc-His of 1 preparation6Protein solution provides), single immunization dosage is " 100 μ of aluminium adjuvant g/, AHc-His6Protein 20 μ g/ Only ", single immunization volume is 100 microlitres/(supplying volume with PBS buffer solution).The side that test group 3 is injected using subcutaneous two o'clock Method is immunized.
The immune time of three test groups is 3 times, each immunization interval 3 weeks.
Control group (15), also known as blank group, without any immune.
Two, malicious processing is attacked
The mouse of three test groups of step 1 carries out attacking poison after the immune completion of third time 2 weeks.
The mouse parallel time of control group carries out attacking poison.
Every group of 15 mouse are divided into 3 subgroups, and each subgroup 5 carries out attacking poison respectively.Attack malicious process: first abdominal cavity note It penetrates 1% yellow Jackets of anesthesia and is anaesthetized and (3h fasting and prohibit drink before anaesthetizing, the dosages of yellow Jackets is 60mg/kg Weight, 1% yellow Jackets normal saline)；After holonarcosis, mouse is fixed on one and desktop into about 45° angle It operates on plate, the right hand is gently clamped mouse tongue with pincet and is lifted up, and left hand takes the mouse laryngoscope with light source to make its sound Door exposure is seen after air pipe inlet the fog-spray nozzle insertion tracheae of hand-held liquid aerosol lung delivery apparatus quickly attacking poison (often The malicious volume of attacking of mouse is 50 μ L)；It attacks poison and completes backed off after random fog-spray nozzle and laryngoscope, and continue to keep mouse head in higher Mouse, is then put into cage by the posture 10-20s of position, warming until mouse is awake to mouse with infrared lamp.Poison is attacked using real Apply the dilution of the BoNT A solution of the preparation of example 1 (solvent is PBS buffer solution).Low dosage subgroup attacks toxic dose 27 times of LD50Dosage.It is 270 times of LD that middle dosage subgroup, which attacks toxic dose,50Dosage.It is 2700 times of LD that high dose subgroup, which attacks toxic dose,50Agent Amount.LD50The 287.8ng/kg weight being calculated in embodiment 2.
Three, survival rate
It is observed 14 days after attacking poison, records mouse survival situation daily.
The survival rate of low dosage subgroup is shown in Fig. 1.
The survival rate of middle dosage subgroup is shown in Fig. 2.
The survival rate of high dose subgroup is shown in Fig. 3.
By the mouse that AHc three times is immunized, by (27 times or 270 times of LD of BoNT A50) after intoxicating, existence Rate is up to 100%, and to 2700 times of LD50BoNT A has partial immunity protective effect.It is immunized without AHc Mouse then survival rate be 0%, it is seen that the transpulmonary delivering mode of AHc be administered have the effect of be subcutaneously injected traditional immunization routes it is suitable Vaccine effectiveness.
Four, antibody level of serum measures
Three time points are as follows: one exempts from and (is immunized for the second time first 2 days), and two exempt from and (are immunized for the third time first 2 days), and three exempt from (attacking before poison 2 days).Respectively at three time points, every group takes 4 mouse at random, is taken a blood sample, is placed at room temperature for by orbital venous plexus After about 2h, 4000rpm is centrifuged 10min, separates serum, freezes after packing in -80 DEG C spare.
Using 6 strain specific antibodies (IgG, IgG1, IgG2a, IgG2b, IgM, IgA) in indirect elisa method detection serum. The AHc-His of 1 preparation of the step of coating antigen is embodiment 1 one6Albumen, peridium concentration are 3 μ g/ml.Secondary antibody is respectively as follows: HRP The goat that the mountain sheep anti-mouse igg of label, mountain sheep anti mouse IgG2a, HRP of mountain sheep anti mouse IgG1, HRP label of HRP label are marked The mountain sheep anti mouse IgM of mountain sheep anti mouse IgA, HRP label of anti-mouse IgG2b, HRP label, is abcam Products.Developing solution For TMB developing solution.It as a result is the positive with P/N >=3.
Blank group: three time points, 6 strain specific antibodies are not detected in mice serum.CpG group: at three Between point, 6 strain specific antibodies are not detected in mice serum.Lung delivery group: it three time points, is not examined in mice serum IgM and IgA are measured, but detects IgG, IgG1, IgG2a and IgG2b of higher level.Subcutaneous group: small three time points IgM and IgA are not detected in mouse serum, IgG2a and IgG2b are not detected in 1 mice serum of time point, only detects IgG And IgG1, IgG, IgG1, IgG2a and IgG2b of higher level are detected in time point 2 and 3 hours time points serum.
As a result see Fig. 4 to Fig. 7 (*, 0.01 < P < 0.05；**0.001<P<0.01；***0<P<0.001).
The result shows that AHc can stimulate mouse to generate specific immune response after being inoculated with as subunit vaccine, and Antibody titer reaches very high level after booster immunization, and the generation of this strain specific antibodies is in the protection process to BoNT/A In play a crucial role.
SEQUENCE LISTING
<110>PLA Academy of Military Sciences's military medical research institute
<120>botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model
<130> GNCYX190918
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 429
<212> PRT
<213> Artificial sequence
<400> 1
Glu Tyr Ile Lys Asn Ile Ile Asn Thr Ser Ile Leu Asn Leu Arg Tyr
1 5 10 15
Glu Ser Asn His Leu Ile Asp Leu Ser Arg Tyr Ala Ser Lys Ile Asn
20 25 30
Ile Gly Ser Lys Val Asn Phe Asp Pro Ile Asp Lys Asn Gln Ile Gln
35 40 45
Leu Phe Asn Leu Glu Ser Ser Lys Ile Glu Val Ile Leu Lys Asn Ala
50 55 60
Ile Val Tyr Asn Ser Met Tyr Glu Asn Phe Ser Thr Ser Phe Trp Ile
65 70 75 80
Arg Ile Pro Lys Tyr Phe Asn Ser Ile Ser Leu Asn Asn Glu Tyr Thr
85 90 95
Ile Ile Asn Cys Met Glu Asn Asn Ser Gly Trp Lys Val Ser Leu Asn
100 105 110
Tyr Gly Glu Ile Ile Trp Thr Leu Gln Asp Thr Gln Glu Ile Lys Gln
115 120 125
Arg Val Val Phe Lys Tyr Ser Gln Met Ile Asn Ile Ser Asp Tyr Ile
130 135 140
Asn Arg Trp Ile Phe Val Thr Ile Thr Asn Asn Arg Leu Asn Asn Ser
145 150 155 160
Lys Ile Tyr Ile Asn Gly Arg Leu Ile Asp Gln Lys Pro Ile Ser Asn
165 170 175
Leu Gly Asn Ile His Ala Ser Asn Asn Ile Met Phe Lys Leu Asp Gly
180 185 190
Cys Arg Asp Thr His Arg Tyr Ile Trp Ile Lys Tyr Phe Asn Leu Phe
195 200 205
Asp Lys Glu Leu Asn Glu Lys Glu Ile Lys Asp Leu Tyr Asp Asn Gln
210 215 220
Ser Asn Ser Gly Ile Leu Lys Asp Phe Trp Gly Asp Tyr Leu Gln Tyr
225 230 235 240
Asp Lys Pro Tyr Tyr Met Leu Asn Leu Tyr Asp Pro Asn Lys Tyr Val
245 250 255
Asp Val Asn Asn Val Gly Ile Arg Gly Tyr Met Tyr Leu Lys Gly Pro
260 265 270
Arg Gly Ser Val Met Thr Thr Asn Ile Tyr Leu Asn Ser Ser Leu Tyr
275 280 285
Arg Gly Thr Lys Phe Ile Ile Lys Lys Tyr Ala Ser Gly Asn Lys Asp
290 295 300
Asn Ile Val Arg Asn Asn Asp Arg Val Tyr Ile Asn Val Val Val Lys
305 310 315 320
Asn Lys Glu Tyr Arg Leu Ala Thr Asn Ala Ser Gln Ala Gly Val Glu
325 330 335
Lys Ile Leu Ser Ala Leu Glu Ile Pro Asp Val Gly Asn Leu Ser Gln
340 345 350
Val Val Val Met Lys Ser Lys Asn Asp Gln Gly Ile Thr Asn Lys Cys
355 360 365
Lys Met Asn Leu Gln Asp Asn Asn Gly Asn Asp Ile Gly Phe Ile Gly
370 375 380
Phe His Gln Phe Asn Asn Ile Ala Lys Leu Val Ala Ser Asn Trp Tyr
385 390 395 400
Asn Arg Gln Ile Glu Arg Ser Ser Arg Thr Leu Gly Cys Ser Trp Glu
405 410 415
Phe Ile Pro Val Asp Asp Gly Trp Gly Glu Arg Pro Leu
420 425
<210> 2
<211> 1287
<212> DNA
<213> Artificial sequence
<400> 2
gaatacatca agaacatcat caatacctcc atcctgaacc tgcgttacga atccaatcac 60
ctgatcgacc tgtctcgtta cgcttccaaa atcaacatcg gttctaaagt taacttcgat 120
ccaatcgaca agaatcagat ccagctgttc aatctggaat cttccaaaat cgaagttatc 180
ctgaagaatg ctatcgtata caactctatg tacgaaaact tctccacctc cttctggatt 240
cgtatcccaa aatacttcaa ctccatctct ctgaacaatg aatacaccat catcaactgc 300
atggaaaaca attctggttg gaaagtatct ctgaactacg gtgaaatcat ctggactctg 360
caggacactc aggaaatcaa acagcgtgtt gtattcaaat actctcagat gatcaacatc 420
tctgactaca tcaatcgttg gatcttcgtt accatcacca acaatcgtct gaataactcc 480
aaaatctaca tcaacggccg tctgatcgac cagaaaccaa tctccaatct gggtaacatc 540
cacgcttcta ataacatcat gttcaaactg gacggttgcc gtgacactca ccgttacatc 600
tggatcaaat acttcaatct gttcgacaaa gaactgaacg aaaaagaaat caaagatctg 660
tacgacaacc agtccaattc tggtatcctg aaagacttct ggggtgacta cctgcagtac 720
gacaaaccat actacatgct gaatctgtac gatccaaaca aatacgttga cgtcaacaat 780
gtaggtatcc gtggttacat gtacctgaaa ggtccacgtg gttctgttat gactaccaac 840
atctacctga actcttccct gtaccgtggt accaaattca tcatcaagaa atacgcgtct 900
ggtaacaagg acaatatcgt tcgtaacaat gatcgtgtat acatcaatgt tgtagttaag 960
aacaaagaat accgtctggc taccaatgct tctcaggctg gtgtagaaaa aatcttgtct 1020
gctctggaaa tcccagacgt tggtaatctg tctcaggtag ttgtaatgaa atccaagaac 1080
gaccagggta tcactaacaa atgcaaaatg aatctgcagg acaacaatgg taacgatatc 1140
ggtttcatcg gtttccacca gttcaacaat atcgctaaac tggttgcttc caactggtac 1200
aatcgtcaga tcgaacgttc ctctcgtact ctgggttgct cttgggagtt catcccagtt 1260
gatgacggtt ggggtgaacg tccactg 1287
<210> 3
<211> 438
<212> PRT
<213> Artificial sequence
<400> 3
Met Glu Tyr Ile Lys Asn Ile Ile Asn Thr Ser Ile Leu Asn Leu Arg
1 5 10 15
Tyr Glu Ser Asn His Leu Ile Asp Leu Ser Arg Tyr Ala Ser Lys Ile
20 25 30
Asn Ile Gly Ser Lys Val Asn Phe Asp Pro Ile Asp Lys Asn Gln Ile
35 40 45
Gln Leu Phe Asn Leu Glu Ser Ser Lys Ile Glu Val Ile Leu Lys Asn
50 55 60
Ala Ile Val Tyr Asn Ser Met Tyr Glu Asn Phe Ser Thr Ser Phe Trp
65 70 75 80
Ile Arg Ile Pro Lys Tyr Phe Asn Ser Ile Ser Leu Asn Asn Glu Tyr
85 90 95
Thr Ile Ile Asn Cys Met Glu Asn Asn Ser Gly Trp Lys Val Ser Leu
100 105 110
Asn Tyr Gly Glu Ile Ile Trp Thr Leu Gln Asp Thr Gln Glu Ile Lys
115 120 125
Gln Arg Val Val Phe Lys Tyr Ser Gln Met Ile Asn Ile Ser Asp Tyr
130 135 140
Ile Asn Arg Trp Ile Phe Val Thr Ile Thr Asn Asn Arg Leu Asn Asn
145 150 155 160
Ser Lys Ile Tyr Ile Asn Gly Arg Leu Ile Asp Gln Lys Pro Ile Ser
165 170 175
Asn Leu Gly Asn Ile His Ala Ser Asn Asn Ile Met Phe Lys Leu Asp
180 185 190
Gly Cys Arg Asp Thr His Arg Tyr Ile Trp Ile Lys Tyr Phe Asn Leu
195 200 205
Phe Asp Lys Glu Leu Asn Glu Lys Glu Ile Lys Asp Leu Tyr Asp Asn
210 215 220
Gln Ser Asn Ser Gly Ile Leu Lys Asp Phe Trp Gly Asp Tyr Leu Gln
225 230 235 240
Tyr Asp Lys Pro Tyr Tyr Met Leu Asn Leu Tyr Asp Pro Asn Lys Tyr
245 250 255
Val Asp Val Asn Asn Val Gly Ile Arg Gly Tyr Met Tyr Leu Lys Gly
260 265 270
Pro Arg Gly Ser Val Met Thr Thr Asn Ile Tyr Leu Asn Ser Ser Leu
275 280 285
Tyr Arg Gly Thr Lys Phe Ile Ile Lys Lys Tyr Ala Ser Gly Asn Lys
290 295 300
Asp Asn Ile Val Arg Asn Asn Asp Arg Val Tyr Ile Asn Val Val Val
305 310 315 320
Lys Asn Lys Glu Tyr Arg Leu Ala Thr Asn Ala Ser Gln Ala Gly Val
325 330 335
Glu Lys Ile Leu Ser Ala Leu Glu Ile Pro Asp Val Gly Asn Leu Ser
340 345 350
Gln Val Val Val Met Lys Ser Lys Asn Asp Gln Gly Ile Thr Asn Lys
355 360 365
Cys Lys Met Asn Leu Gln Asp Asn Asn Gly Asn Asp Ile Gly Phe Ile
370 375 380
Gly Phe His Gln Phe Asn Asn Ile Ala Lys Leu Val Ala Ser Asn Trp
385 390 395 400
Tyr Asn Arg Gln Ile Glu Arg Ser Ser Arg Thr Leu Gly Cys Ser Trp
405 410 415
Glu Phe Ile Pro Val Asp Asp Gly Trp Gly Glu Arg Pro Leu Leu Glu
420 425 430
His His His His His His
435
<210> 4
<211> 1676
<212> DNA
<213> Artificial sequence
<400> 4
catatgagcg ataaaattat tcacctgact gacgacagtt ttgacacgga tgtactcaaa 60
gcggacgggg cgatcctcgt cgatttctgg gcagagtggt gcggtccgtg caaaatgatc 120
gccccgattc tggatgaaat cgctgacgaa tatcagggca aactggccgt tgcaaaactg 180
aacatcgatc aaaaccctgg cactgcgccg aaatatggca tccgtggtat cccgactctg 240
ctgctgttca aaaacggtga agtggcggca accaaagtgg gtgcactgtc taaaggtcag 300
ttgaaagagt tcctcgacgc taatctggcg ggagcgggat ccggtaagga ggaattctaa 360
tggaatacat caagaacatc atcaatacct ccatcctgaa cctgcgttac gaatccaatc 420
acctgatcga cctgtctcgt tacgcttcca aaatcaacat cggttctaaa gttaacttcg 480
atccaatcga caagaatcag atccagctgt tcaatctgga atcttccaaa atcgaagtta 540
tcctgaagaa tgctatcgta tacaactcta tgtacgaaaa cttctccacc tccttctgga 600
ttcgtatccc aaaatacttc aactccatct ctctgaacaa tgaatacacc atcatcaact 660
gcatggaaaa caattctggt tggaaagtat ctctgaacta cggtgaaatc atctggactc 720
tgcaggacac tcaggaaatc aaacagcgtg ttgtattcaa atactctcag atgatcaaca 780
tctctgacta catcaatcgt tggatcttcg ttaccatcac caacaatcgt ctgaataact 840
ccaaaatcta catcaacggc cgtctgatcg accagaaacc aatctccaat ctgggtaaca 900
tccacgcttc taataacatc atgttcaaac tggacggttg ccgtgacact caccgttaca 960
tctggatcaa atacttcaat ctgttcgaca aagaactgaa cgaaaaagaa atcaaagatc 1020
tgtacgacaa ccagtccaat tctggtatcc tgaaagactt ctggggtgac tacctgcagt 1080
acgacaaacc atactacatg ctgaatctgt acgatccaaa caaatacgtt gacgtcaaca 1140
atgtaggtat ccgtggttac atgtacctga aaggtccacg tggttctgtt atgactacca 1200
acatctacct gaactcttcc ctgtaccgtg gtaccaaatt catcatcaag aaatacgcgt 1260
ctggtaacaa ggacaatatc gttcgtaaca atgatcgtgt atacatcaat gttgtagtta 1320
agaacaaaga ataccgtctg gctaccaatg cttctcaggc tggtgtagaa aaaatcttgt 1380
ctgctctgga aatcccagac gttggtaatc tgtctcaggt agttgtaatg aaatccaaga 1440
acgaccaggg tatcactaac aaatgcaaaa tgaatctgca ggacaacaat ggtaacgata 1500
tcggtttcat cggtttccac cagttcaaca atatcgctaa actggttgct tccaactggt 1560
acaatcgtca gatcgaacgt tcctctcgta ctctgggttg ctcttgggag ttcatcccag 1620
ttgatgacgg ttggggtgaa cgtccactgc tcgagcacca ccaccaccac cactag 1676

Claims (10)

1. a kind of BoNT A vaccine, effective component is the aerosol of particular solution；Contain in the particular solution Specific protein and Mucosal Adjuvants；The specific protein is AHc albumen or the fusion protein with AHc albumen；Specific protein Quality proportioning with Mucosal Adjuvants is 1:0.5-1.5；
AHc albumen is following (a1) or (a2):
(a1) protein shown in the sequence 1 of sequence table；
(a2) by protein shown in sequence 1 in sequence table by one or several amino acid residues substitution and/or missing and/ Or addition and protein with the same function as derived from it.
2. a kind of for preventing and/or treating the external member of BoNT A poisoning, including specific protein, mucosa-immune assistant Agent and liquid aersol lung delivery apparatus；The specific protein is AHc albumen or the fusion protein with AHc albumen；Specific egg White and Mucosal Adjuvants quality proportionings are 1:0.5-1.5；
AHc albumen is following (a1) or (a2):
(a1) protein shown in the sequence 1 of sequence table；
(a2) by protein shown in sequence 1 in sequence table by one or several amino acid residues substitution and/or missing and/ Or addition and protein with the same function as derived from it.
3. a kind of BoNT A vaccine, effective component is the aerosol of specific protein solution；The specific protein is AHc albumen or fusion protein with AHc albumen；AHc albumen is following (a1) or (a2):
(a1) protein shown in the sequence 1 of sequence table；
(a2) by protein shown in sequence 1 in sequence table by one or several amino acid residues substitution and/or missing and/ Or addition and protein with the same function as derived from it.
4. a kind of for preventing and/or treating the external member of BoNT A poisoning, including specific protein and liquid aersol Lung delivery apparatus；The specific protein is AHc albumen or the fusion protein with AHc albumen；AHc albumen be following (a1) or (a2):
(a1) protein shown in the sequence 1 of sequence table；
(a2) by protein shown in sequence 1 in sequence table by one or several amino acid residues substitution and/or missing and/ Or addition and protein with the same function as derived from it.
5. a kind of for preventing and/or treating the vaccine of BoNT A poisoning, effective component is specific protein and sticks Film immunologic adjuvant；The specific protein is AHc albumen or the fusion protein with AHc albumen；Specific protein and mucosa-immune assistant The quality proportioning of agent is 1:0.5-1.5；AHc albumen is following (a1) or (a2):
(a1) protein shown in the sequence 1 of sequence table；
(a2) by protein shown in sequence 1 in sequence table by one or several amino acid residues substitution and/or missing and/ Or addition and protein with the same function as derived from it.
6. vaccine as claimed in claim 5, it is characterised in that: the vaccine is lung delivery of vaccines.
7. specific protein, Mucosal Adjuvants and lung delivery apparatus are preparing the application in product；The purposes of the product is pre- Anti- and/or treatment BoNT A poisoning；The specific protein is AHc albumen or the fusion protein with AHc albumen； The quality proportioning of specific protein and Mucosal Adjuvants is 1:0.5-1.5；
AHc albumen is following (a1) or (a2):
(a1) protein shown in the sequence 1 of sequence table；
(a2) by protein shown in sequence 1 in sequence table by one or several amino acid residues substitution and/or missing and/ Or addition and protein with the same function as derived from it.
8. a kind of method for preparing botulinum toxin intoxicating animal model includes the following steps: botulinum toxin solution passing through liquid Aerosol lung is delivered to experimental animal, obtains botulinum toxin intoxicating animal model.
9. method according to claim 8, it is characterised in that: the botulinum toxin is BoNT A.
10. method as claimed in claim 8 or 9, it is characterised in that: the experimental animal is mouse.
CN201910384771.8A 2019-05-09 2019-05-09 Botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model Pending CN110141661A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910384771.8A CN110141661A (en) 2019-05-09 2019-05-09 Botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910384771.8A CN110141661A (en) 2019-05-09 2019-05-09 Botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model

Publications (1)

Publication Number Publication Date
CN110141661A true CN110141661A (en) 2019-08-20

Family

ID=67595057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910384771.8A Pending CN110141661A (en) 2019-05-09 2019-05-09 Botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model

Country Status (1)

Country Link
CN (1) CN110141661A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550769A (en) * 2019-09-30 2022-12-05 イプセン バイオファーム リミテッド Use of Clostridial Neurotoxin Mutants for the Treatment of Neurological Disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101054582A (en) * 2006-10-23 2007-10-17 中国人民解放军军事医学科学院生物工程研究所 A-type kreotoxin receptor combination region Hc, coding protein and application thereof
CN108619500A (en) * 2018-06-05 2018-10-09 中国人民解放军军事科学院军事医学研究院 A kind of A, B, E, Botulinum toxin F tetravalent vaccine and preparation method thereof
CN110327314A (en) * 2019-07-23 2019-10-15 中国人民解放军军事科学院军事医学研究院 A kind of botulinum toxin type A AHc subunit vaccine Foradil Aerolizer formoterol fumarate of aerosolizable

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101054582A (en) * 2006-10-23 2007-10-17 中国人民解放军军事医学科学院生物工程研究所 A-type kreotoxin receptor combination region Hc, coding protein and application thereof
CN108619500A (en) * 2018-06-05 2018-10-09 中国人民解放军军事科学院军事医学研究院 A kind of A, B, E, Botulinum toxin F tetravalent vaccine and preparation method thereof
CN110327314A (en) * 2019-07-23 2019-10-15 中国人民解放军军事科学院军事医学研究院 A kind of botulinum toxin type A AHc subunit vaccine Foradil Aerolizer formoterol fumarate of aerosolizable

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. GAN等: "Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice", 《NPJ VACCINES》 *
J.-B. PARK等: "Inhalational Poisoning by Botulinum Toxin and Inhalation Vaccination with Its Heavy-Chain Component", 《INFECT IMMUN》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550769A (en) * 2019-09-30 2022-12-05 イプセン バイオファーム リミテッド Use of Clostridial Neurotoxin Mutants for the Treatment of Neurological Disorders

Similar Documents

Publication Publication Date Title
CN102807621B (en) Comprise the fusion rotein of diphtheria toxin non-toxic mutant CRM197 or its fragment
US20120258129A1 (en) Mycobacterium tuberculosis fusion protein and uses thereof
Allen et al. A single peptide from the major outer membrane protein of Chlamydia trachomatis elicits T cell help for the production of antibodies to protective determinants.
US20100280229A1 (en) Polypeptide
KR102094569B1 (en) Vaccine for preventing porcine edema disease
CN113173977A (en) Bifunctional antigen, preparation method and application thereof
CN110141661A (en) Botulinal toxin A Hc vaccine liquid aersol lung delivers immune mouse model
KR102608642B1 (en) Pneumococcal vaccine combining selected alpha-helical domains and proline-rich domains of pneumococcal surface protein A
WO2019076218A1 (en) Mutant of h3n2 subtype influenza virus hemagglutinin protein and use thereof
CN108578686A (en) A method of preparing clostridiosis of sheep genetic engineering subunit vaccine
KR20070102429A (en) Using a reverse genetic engineering platform to produce protein vaccine and protein vaccine of avian influenza virus
CN102134279B (en) Fusion protein and encoding gene thereof as well as application of fusion protein
CN110327314A (en) A kind of botulinum toxin type A AHc subunit vaccine Foradil Aerolizer formoterol fumarate of aerosolizable
JP6541158B2 (en) Mucosal vaccine adjuvant
RU2727476C2 (en) Antigens and antigen compositions
CN114437235B (en) Recombinant fusion protein of streptococcus equi subspecies 8 proteins, and preparation method and application thereof
Zakowska et al. Protective antigen domain 4 of Bacillus anthracis as a candidate for use as vaccine for anthrax
CN108619500A (en) A kind of A, B, E, Botulinum toxin F tetravalent vaccine and preparation method thereof
CN110483624B (en) Borrelia garinii OspA protein C-terminal peptide segment and application thereof
CN101134781A (en) Recombinant fusion protein carrying anthrax protective antigens epitope inserted to hepatitis B core antigen protein or its fragment and uses thereof
Jin et al. Long-lasting specific antibodies against P277 induced by mucosal administration of P277 repeat sequences carried by Hsp65 in the absence of adjuvants
EP3892298A1 (en) Epitopes having sequence homology to coronavirus spike protein subunit and uses thereof
Starodubova et al. Rabies Virus Glycoprotein with a Consensus Amino Acid Sequence and a Lysosome Targeting Signal Causes Effective Production of Antibodies in DNA-Immunized Mice
CN101204580B (en) Application of Vibrio alginolyticus-OmpA as animal immunity regulator
Hausman et al. Immune response to dimeric subunits of the pertussis toxin B oligomer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination